

Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: **PFE US EQUITY**

Pfizer Inc (New York: PFE, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos


Website	www.pfizer.com
Number of Employees	78,500
Ticker:	PFE US

235 East 42nd Street New York, NY 10017 United States
Phone : 1-212-733-2323
Fax : 1-212-573-7851

↓ **53.00** -0.38 (-0.71%)

FECHA: 30/06/2021

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	53.00	Market Cap (MM)	297,481.9
Open	53.02	Shares Out. (MM)	5,612.9
Previous Close	53.38	Float %	100.0%
Change	-0.48	Shares sold short (MM)	64,075,070.0
Change %	-0.89	Dividend Yield %	3.0
Day High/Day Low	53.4 / 52.6	Diluted EPS Excl. XO	3.4
52 Wk High/52 Wk low	61.7 / 33.4	P / Diluted EPS Before XO	16.0
Volume (MM)	24.92	Beta	0.68
Avg. Vol - 3 mo (MM)	44.27		



Financial Information (Currency: USD, in mm)			
Revenue - LTM	69,337.0	Cash & ST Invest.	12,221
EBIT - LTM	17,046.0	Total Assets	154,229.0
EBITDA - LTM	22,006.0	Total Debt	41,271.0
Net Income - LTM	19,180.0	Total Liabilities	90,756.0
Total Enterprise Value	307,940	Total Equity	63,473.0
TEV/ Total Revenue	3.6 x	Cash from Operations - LTM	32,291.0
TEV/ EBITDA	11.4 x	Cash From Investing - LTM	-11,630.0
		Cash from Financing -LTM	-20,254.0


Company Notes	
2015 Q3	
GAAP Net Income Includes: (in millions, pre-tax)	2014 Q1
A loss of \$470.000 from Asset Write Down	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$529.000 from Restructuring	A loss of \$140 from Restructuring
A loss of \$163.000 from Impairment of Intangibles	A loss of \$694 from Legal Expense
A loss of \$124.000 from Merger & Acquisition.	A loss of \$139 from Impairments and M & A Expense
A gain of \$35.000 from Disposal of assets.	A gain of \$210 from Asset Disposal, Derivatives, and other
A loss of 97.000 from various one time items.	
2015 Q2	
GAAP Net Income Includes: (in millions, pre-tax)	2013 A1
A loss of \$304.000 from Other One Time Items	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$25.000 from Asset Write Down	A loss of \$1431 from Restructuring, A gain of \$1321 from Legal Expense, A loss of \$144 from M & A Expense, A gain of \$38 from Derivatives, A loss of \$1224 from Impairments, A gain of \$125
A loss of \$68.000 from Merger/Acquisition Expense	from Derivatives, A gain of \$195 from Sale of Investment
A gain of \$ 5.000 from Investments, a gain from \$ 15.000 fr from Asset Disposal, A gain of \$195 from Sale of Investment	disposal of asset, A loss of \$25.000 from impairment of asse A gain of \$10,623.000 from Discontinued Operations
disposal of asset, A loss of \$25.000 from impairment of asse A gain of \$10,623.000 from Discontinued Operations	
2015 Q1	
GAAP Net Income includes, (in millions, after-tax):	2013 Q4
a loss of \$17.000 from Acquisition/Merger	GAAP Net Income Includes: (in millions, pre-tax)
a loss of \$167.000 from Various One-Time Items	A loss of \$708 from Restructuring, A loss of \$120 from Legal Expense, A loss of \$34 from M & A Expense, A gain of \$5 from Derivatives, A loss of \$176 from Impairments, A gain of \$125 from Assets Disposal, A gain of \$95 from Sale of Investment
a gain of \$5.000 from Discontinued Operations	a loss of \$58.000 from Discontinued Operations
2014 A1	
GAAP Net Income includes, (in millions):	2013 Q3
a pre-tax gain of \$288.000 from Disposal of Assets	GAAP Net Income includes, (in millions, after-tax):
a pre-tax loss of \$1,630.000 from Impairment/Legal	a loss of \$54.000 from Acquisition/Merger
a pre-tax loss of \$250.000 from Restructuring/Acquisition	a loss of \$1,223.000 from Various One-Time Items
an after-tax gain of \$48.000 from Discontinued Operations	a gain of \$11.000 from Discontinued Operations

Key Board Members			
Name	Title	Organization	
Ronald E Blaylock "Ron"	Managing Partner/Co-Founder	Gennx360 Capital Partners	
	Founder	Blaylock & Co Inc	
	Board Member	Advantage Solutions Inc	
	Board Member	Pfizer Inc	
	Board Member	Carmax Inc	
	Board Member	Wf Berkeley Corp	
Susan Desmond-Hellmann "Sue"	Board Member	Mebane Charitable Foundation I	
	Board Member	Pfizer Inc	
	Board Member	Pfizer Venture Investments	
Suzanne Nora Johnson	Co-Chairman	Brookings Institution/The	
	Chairman	Intuit Inc	
	Board Member	Pfizer Inc	
	Trustee	University Of Southern Califor	
	Chairman	John & Mary R Markle Foundatio	
	Trustee	Carnegie Institution Of Washin	
	Trustee	University Of Southern Califor	
Shantanu Narayan	Board Member	Women'S World Banking	
	Board Member	Technoserve Inc	
	Board Member	Council For Excellence In Govt	
	Board Member	Children Now Inc	
	Board Member	American Red Cross	
	Board Member	Children Now Inc	
	Co-Founder	Pictra Inc	
	Vice Chairman	Us-India Strategic Partnership	
	Chairman/President/Ceo	Adobe Ventures Lp	
	Chairman/Ceo	Adobe Inc	
Lead Director	Pfizer Inc		
Susan Hockfield	Chairman	Adobe Foundation	
	Overseer	Boston Symphony Orchestra Inc	

Ticker:	PFE US EQUITY										
Period Type:	Annuals										
Company:	Pfizer Inc										
Sector:	Salud			Industry: Productos farmacéuticos				Sub-Industry: Productos farmacéuticos			
Annuals FY:	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY


Key Financials	Actuals											LTM		Estimates	
	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	03/10/2021	03/10/2021	31/12/2021	31/12/2022	31/12/2023				
For the Fiscal Period Ending	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD			
Total Revenue	49,605.0	48,851.0	52,824.0	52,546.0	53,647.0	41,172.0	41,908.0	69,337.0	24,169.5	24,169.5	24,169.5				
<i>Growth Over Prior Year</i>	(3.8%)	(1.5%)	8.1%	(0.5%)	2.1%	(23.3%)	1.8%	70.5%	106.9%	106.9%	106.9%				
Gross Profit	40,028.0	39,203.0	40,495.0	41,318.0	42,399.0	32,921.0	33,216.0	45,185.0	--	--	--				
<i>Margin %</i>	80.7%	80.3%	76.7%	78.6%	79.0%	80.0%	79.3%	65.2%	--	--	--				
EBITDA	18,786.0	16,981.0	17,763.0	19,991.0	20,385.0	20,972.0	13,336.0	22,006.0	6,530.2	6,530.2	6,530.2				
<i>Margin %</i>	37.9%	34.8%	33.6%	38.0%	38.0%	50.9%	31.8%	31.7%	27.0%	27.0%	27.0%				
EBIT	13,249.0	11,824.0	12,006.0	13,722.0	14,001.0	14,800.0	8,166.0	17,046.0	5,540.3	5,540.3	5,540.3				
<i>Margin %</i>	26.7%	24.2%	22.7%	26.1%	26.1%	35.9%	19.5%	24.6%	22.9%	22.9%	22.9%				
Earnings from Cont. Ops.	9,120.0	6,975.0	7,228.0	21,353.0	11,179.0	10,867.0	7,020.0	18,957.0	--	--	--				
<i>Margin %</i>	18.4%	14.3%	13.7%	40.6%	20.8%	26.4%	16.8%	27.3%	--	--	--				
Net Income	9,135.0	6,960.0	7,215.0	21,308.0	11,153.0	16,273.0	9,616.0	19,180.0	5,026.1	5,026.1	5,026.1				
<i>Margin %</i>	18.4%	14.2%	13.7%	40.6%	20.8%	39.5%	22.9%	27.7%	20.8%	20.8%	20.8%				
Diluted EPS Excl. Extra Items	1.4	1.1	1.2	3.5	1.9	1.9	1.2	3.3	0.9	0.9	0.9				
<i>Growth Over Prior Year</i>	(14.5%)	(21.3%)	5.4%	200.9%	(47.2%)	2.7%	(35.1%)	281.6%	109.0%	109.0%	109.0%				

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	53.00
Shares Out.	5,612.87
Market Capitalization (USD)	297,481.93
- Cash & Short Term Investments	29,696.00
+ Total Debt	39,879.00
+ Pref. Equity	0.00
+ Total Minority Interest	275.00
= Total Enterprise Value (USD)	307,939.93
Book Value of Common Equity	75,692.00
+ Pref. Equity	0.00
+ Total Minority Interest	275.00
+ Total Debt	39,879.00
= Total Capital	115,846.00



Valuation Multiples based on Current Capitalization					
For the Fiscal Period Ending	Actual		Estimates		
	03/10/2021	03/10/2021	03/10/2021	03/10/2021	03/10/2021
TEV/Total Revenue	5.6x	3.6x	--	--	--
TEV/EBITDA	17.6x	11.4x	--	--	--
TEV/EBIT	28.5x	14.7x	--	--	--
P/Diluted EPS Before Extra	29.7x	12.9x	--	--	--
P/BV	3.2x	3.2x	3.9x	3.9x	3.9x
Price/Tang BV	--	--	--	--	--

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	15.5x	8.5x	8.5x	8.5x
TEV / EBITDA	11.4x	0.0x	0.0x	0.0x
Price / CF	9.2x	7.3x	7.3x	7.3x
Price / Book	3.9x	3.9x	3.9x	3.9x
Dividend Yield	3.0x	3.1x	3.1x	3.1x



Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Income Statement											
Income Sheet as of:	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	67,057.00	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	41,172.00	41,908.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	67,057.00	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	41,172.00	41,908.00
Cost Of Goods Sold	15,838.00	14,076.00	9,821.00	9,586.00	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,251.00	8,692.00
Gross Profit	51,219.00	51,183.00	44,836.00	41,998.00	40,028.00	39,203.00	40,495.00	41,318.00	42,399.00	32,921.00	33,216.00
Selling General & Admin Exp.	22,806.00	21,762.00	16,981.00	15,537.00	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,265.00	12,209.00
R & D Exp.	9,392.00	9,074.00	7,482.00	6,678.00	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,394.00	9,405.00
Depreciation & Amort.	5,403.00	5,544.00	5,109.00	4,599.00	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,462.00	3,436.00
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	37,601.00	36,380.00	29,572.00	26,814.00	26,779.00	27,379.00	28,489.00	27,596.00	28,398.00	18,121.00	25,050.00
Operating Income	13,618.00	14,803.00	15,264.00	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,800.00	8,166.00
Interest Expense	1,797.00	1,681.00	1,522.00	1,414.00	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00
Interest Income	402.00	456.00	382.00	403.00	425.00	471.00	470.00	391.00	333.00	225.00	73.00
Net Interest Exp.	1,395.00	1,225.00	1,140.00	1,011.00	935.00	728.00	716.00	879.00	983.00	1,348.00	1,376.00
Currency Exchange Gains (Loss)	-	-	-	-	-	806.00	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	3,096.00	1,274.00	2,882.00	(1,543.00)	74.00	1,325.00	2,939.00	538.00	1,133.00	1,967.00	(707.00)
EBT Excl. Unusual Items	9,127.00	12,304.00	11,242.00	15,716.00	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,485.00	7,497.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	(155.00)	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	310.00	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	9,282.00	12,304.00	11,242.00	15,716.00	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,485.00	7,497.00
Income Tax Expense	1,071.00	3,909.00	2,221.00	4,306.00	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	618.00	477.00
Earnings from Cont. Ops.	8,211.00	8,395.00	9,021.00	11,410.00	9,120.00	6,975.00	7,228.00	21,353.00	11,179.00	10,867.00	7,020.00
Extraord. Item & Account. Change	(77.00)	(1,654.00)	(5,577.00)	(10,662.00)	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,435.00)	(2,631.00)
Minority Int. in Earnings	31.00	40.00	28.00	69.00	33.00	26.00	31.00	47.00	36.00	29.00	35.00
Net Income	8,257.00	10,009.00	14,570.00	22,003.00	9,135.00	6,960.00	7,215.00	21,308.00	11,153.00	16,273.00	9,616.00
Pref. Dividends	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	8,254.00	10,006.00	14,568.00	22,001.00	9,133.00	6,958.00	7,213.00	21,307.00	11,152.00	16,272.00	9,616.00
Abnormal Losses (Gains)	8,078.00	6,326.00	5,985.00	1,106.00	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	3,849.00
Tax Effect on Abnormal Items	(4,400.75)	(1,842.00)	(2,791.00)	(344.00)	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(813.67)
NI to Common Excl. Extra Items	11,931.25	14,490.00	17,762.00	22,763.00	11,484.70	10,447.85	12,925.85	12,464.46	13,531.33	12,667.11	12,651.33
Per Share Items											
Basic EPS	1.03	1.28	1.96	3.23	1.44	1.13	1.18	3.57	1.90	2.92	1.73
Basic EPS Excl. Extra Items	1.02	1.07	1.21	1.67	1.43	1.13	1.18	3.57	1.90	1.95	1.26
Weighted Avg. Basic Shares Out.	8,036.00	7,817.00	7,442.00	6,813.00	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00
Diluted EPS	1.02	1.27	1.94	3.19	1.42	1.11	1.17	3.52	1.87	2.87	1.71
Diluted EPS Excl. Extra Items	1.01	1.06	1.20	1.65	1.41	1.11	1.17	3.52	1.86	1.91	1.24
Weighted Avg. Diluted Shares Out.	8,074.00	7,870.00	7,508.00	6,895.00	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00
Normalized Basic EPS	2.23	2.31	2.19	2.22	2.26	2.20	2.40	2.65	3.00	2.95	2.22
Normalized Diluted EPS	1.47	1.63	1.63	1.76	1.78	1.67	2.10	2.06	2.26	1.27	1.78
Dividends per Share	0.72	0.80	0.88	0.96	1.04	1.12	1.20	1.30	1.38	1.46	1.53
Payout Ratio %	72.94	77.97	72.84	57.68	72.65	99.57	101.55	36.43	72.73	75.03	121.68
Supplemental Items											
EBITA	19,122.00	20,388.00	20,373.00	19,783.00	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	19,262.00	11,602.00
EBIT	13,618.00	14,803.00	15,264.00	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,800.00	8,166.00
As Reported Total Revenue*	67,057.00	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	41,172.00	41,908.00
Effective Tax Rate %	11.54	31.77	19.76	27.40	25.49	22.20	13.45	-	5.94	5.38	6.36
Normalized Net Income	11,854.25	12,836.00	12,185.00	12,101.00	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,232.11	10,020.33
Interest Capitalized	36.00	50.00	41.00	32.00	41.00	32.00	61.00	72.00	73.00	88.00	96.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	405.00	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	688.00	756.00
Stock-Based Comp., Total	405.00	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	688.00	756.00

Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Balance Sheet	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Balance Sheet as of:	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	1,735.00	3,182.00	10,081.00	2,183.00	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,784.00
Short Term Investments	26,277.00	23,270.00	22,318.00	30,225.00	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00
Total Cash & ST Investments	28,012.00	26,452.00	32,399.00	32,408.00	36,122.00	23,290.00	17,850.00	19,992.00	18,833.00	9,646.00	12,221.00
Accounts & Notes Receivable	13,380.00	13,058.00	10,675.00	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00
Total Receivables	13,380.00	13,058.00	10,675.00	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00
Inventories	8,275.00	6,610.00	6,076.00	6,166.00	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,046.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	11,346.00	14,697.00	15,681.00	8,313.00	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,870.00
Total Current Assets	61,013.00	60,817.00	64,831.00	56,244.00	55,595.00	43,804.00	38,949.00	41,141.00	49,926.00	32,803.00	35,067.00
Net Property, Plant & Equipment	18,645.00	15,921.00	13,213.00	12,397.00	11,760.00	13,766.00	13,318.00	13,865.00	13,385.00	14,257.00	15,293.00
Long-term Investments	9,747.00	9,814.00	14,149.00	16,406.00	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00
Deferred Charges, LT	-	-	1,565.00	1,554.00	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00
Other Long-Term Assets	105,609.00	101,450.00	92,040.00	85,500.00	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,224.00
Total Assets	195,014.00	188,002.00	185,798.00	172,101.00	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00
LIABILITIES											
Accrued Exp.	2,080.00	2,120.00	1,875.00	1,792.00	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,058.00
Short-term Borrowings	5,603.00	4,016.00	6,424.00	6,027.00	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,024.00
Accounts Payable	3,994.00	3,678.00	2,921.00	3,234.00	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,887.00	4,309.00
Curr. Income Taxes Payable	951.00	1,009.00	979.00	678.00	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00
Other Current Liabilities	16,008.00	18,086.00	16,987.00	11,635.00	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,582.00	14,480.00
Total Current Liabilities	28,636.00	28,909.00	29,186.00	23,366.00	21,587.00	29,398.00	31,115.00	30,427.00	31,858.00	37,303.00	25,920.00
Long-Term Debt	38,410.00	34,926.00	31,036.00	30,462.00	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,247.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	39,703.00	41,546.00	43,898.00	41,653.00	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,589.00
Total Liabilities	106,749.00	105,381.00	104,120.00	95,481.00	95,945.00	102,383.00	111,775.00	100,141.00	95,664.00	104,147.00	90,756.00
Pref. Stock, Non-Redeem.	52.00	45.00	39.00	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-
Total Pref. Equity	52.00	45.00	39.00	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-
Minority Interest	452.00	431.00	418.00	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00
Additional Paid In Capital	71,204.00	71,868.00	73,056.00	77,736.00	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00
Retained Earnings	42,716.00	46,210.00	54,240.00	69,732.00	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	96,770.00
Treasury Stock	(22,712.00)	(31,801.00)	(40,122.00)	(67,923.00)	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)
Comprehensive Inc. and Other	(3,447.00)	(4,132.00)	(5,953.00)	(3,271.00)	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,638.00)	(11,688.00)
Total Common Equity	88,213.00	82,576.00	81,639.00	76,587.00	71,592.00	64,972.00	59,816.00	71,635.00	63,739.00	63,430.00	63,473.00
Total Equity	88,265.00	82,621.00	81,678.00	76,620.00	71,621.00	64,998.00	59,840.00	71,656.00	63,758.00	63,447.00	63,473.00
Total Liabilities And Equity	195,014.00	188,002.00	185,798.00	172,101.00	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00
Supplemental Items											
Total Shares Out. on Filing Date	8,012.00	7,575.00	7,276.00	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00
Total Shares Out. on Balance Sheet Date	8,012.00	7,575.00	7,276.00	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00
Book Value/Share	10.95	10.84	11.16	11.92	11.33	10.48	9.81	11.92	11.09	11.41	11.36
Tangible Book Value	(13,722.00)	(13,608.00)	(7,586.00)	(5,630.00)	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,011.00)	(14,810.00)
Tangible Book Value/Share	(1.71)	(1.80)	(1.04)	(0.88)	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.66)
Total Debt	44,013.00	38,942.00	37,460.00	36,489.00	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,271.00
Net Debt	16,001.00	12,490.00	5,061.00	4,081.00	560.00	15,609.00	24,236.00	23,499.00	22,907.00	43,803.00	29,050.00
Total Minority Interest	452.00	431.00	418.00	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	883.00	785.00	448.00	505.00	510.00	867.00	793.00	788.00	546.00	672.00	738.00
Work in Progress Inventory	3,727.00	3,514.00	3,374.00	3,445.00	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,430.00
Finished Goods Inventory	3,665.00	2,311.00	2,254.00	2,216.00	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,878.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	208.00	226.00	324.00	478.00	412.00	384.00	609.00	584.00	541.00	493.00	508.00
Full Time Employees	110,600.00	103,700.00	91,500.00	77,700.00	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00

Ticker: PFE US EQUITY
 Period Type: Annuals

Sort: Ascend
 Consolidated: Yes

Accounting: Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Multiples		31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
TEV / LTM Total Revenue	Close	2.3x	2.7x	3.4x	3.9x	4.0x	4.4x	4.2x	4.6x	5.1x	6.3x	5.6x
	Average	3.2x	2.5x	2.9x	3.8x	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x
	High	3.7x	2.8x	3.5x	4.2x	4.1x	4.5x	5.0x	4.7x	5.5x	6.3x	6.8x
	Low	2.3x	2.2x	2.6x	3.5x	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x
TEV / LTM EBITDA	Close	7.1x	7.5x	8.2x	9.3x	10.5x	12.7x	12.5x	12.0x	13.4x	12.4x	17.6x
	Average	9.9x	7.7x	7.9x	9.0x	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x
	High	11.6x	8.4x	8.7x	10.0x	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x
	Low	7.1x	6.7x	7.3x	8.3x	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.6x
TEV / LTM EBIT	Close	11.5x	11.9x	12.3x	13.2x	14.9x	18.2x	18.5x	17.5x	19.5x	17.6x	28.5x
	Average	14.1x	12.5x	12.6x	13.5x	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x
	High	16.5x	13.7x	14.0x	15.0x	14.9x	18.2x	20.5x	21.2x	19.6x	19.6x	28.5x
	Low	11.5x	10.9x	11.6x	12.5x	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x
Price / LTM EPS	Close	11.9x	13.3x	15.4x	17.4x	17.5x	19.4x	15.5x	17.6x	19.3x	30.7x	20.7x
	Average	9.6x	12.6x	13.5x	16.9x	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.4x
	High	11.5x	14.1x	15.1x	18.8x	17.6x	19.3x	21.2x	16.8x	21.3x	29.1x	33.4x
	Low	8.1x	10.8x	12.2x	15.1x	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	20.7x
Price / Book Value	Close	1.6x	2.0x	2.2x	2.6x	2.7x	3.1x	3.3x	3.0x	3.9x	3.4x	3.2x
	Average	1.4x	1.7x	2.0x	2.5x	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x
	High	1.7x	1.9x	2.3x	2.7x	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x
	Low	1.2x	1.4x	1.8x	2.2x	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	--	--	--	--
	Average	--	--	--	--	--	--	--	--	--	--	--
	High	--	--	--	--	--	--	--	--	--	--	--
	Low	--	--	--	--	--	--	--	--	--	--	--
Price / Cash Flow	Close	12.3x	8.4x	11.1x	11.8x	11.6x	13.6x	12.4x	12.9x	16.2x	17.3x	14.2x
	Average	6.7x	13.0x	8.5x	12.2x	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x
	High	11.6x	14.5x	10.6x	13.6x	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x
	Low	5.7x	7.9x	7.7x	10.9x	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x
TEV / LTM FCF	Close	14.2x	9.1x	12.1x	12.7x	12.4x	15.0x	14.0x	14.6x	18.6x	20.7x	16.8x
	Average	7.3x	14.9x	9.3x	13.3x	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.5x
	High	13.4x	16.7x	11.5x	14.7x	12.8x	14.2x	16.4x	15.3x	17.6x	19.7x	22.5x
	Low	6.1x	8.6x	8.4x	11.8x	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x
Dividend Yield	Close	4.1	3.7	3.5	3.1	3.3	3.5	3.7	3.6	3.2	3.7	4.2
	Average	5.1	3.9	3.7	3.2	3.3	3.3	3.6	3.7	3.5	3.7	4.2
	High	6.0	4.6	4.0	3.6	3.7	3.7	4.1	4.1	4.1	4.3	5.4
	Low	4.2	3.5	3.2	2.9	3.1	3.0	3.2	3.4	3.0	3.3	3.4

Ticker:	PFE US EQUITY
Period Type:	Quarters

PFE US EQUITY	Ascend
Consolidated	Yes

Accounting	Mixed
------------	-------

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Ratios	31/03/2019	30/06/2019	29/09/2019	31/12/2019	29/03/2020	28/06/2020	27/09/2020	31/12/2020	04/04/2021	04/07/2021	03/10/2021
Profitability											
Return on Assets	7.2%	7.9%	9.6%	10.0%	9.8%	8.5%	4.6%	5.5%	6.4%	7.2%	10.7%
Return on Capital	11.8%	12.6%	15.2%	16.0%	15.5%	13.1%	7.4%	9.3%	10.4%	11.6%	16.7%
Return on Equity	17.8%	19.6%	23.8%	25.7%	25.4%	22.9%	12.2%	14.1%	15.6%	18.6%	27.2%
Margin Analysis											
Gross Margin	81.5%	80.6%	79.5%	80.0%	80.8%	81.5%	80.5%	75.0%	71.1%	62.9%	58.6%
SG&A Margin	25.2%	26.1%	25.2%	34.7%	24.3%	25.6%	24.9%	30.7%	18.2%	14.7%	11.3%
EBITDA Margin	38.8%	39.6%	53.9%	53.4%	52.9%	51.0%	32.2%	30.9%	31.6%	33.0%	31.7%
EBIT Margin	26.9%	27.5%	41.5%	40.9%	40.6%	38.7%	19.9%	19.5%	21.1%	24.0%	24.6%
Earnings from Cont. Ops Margin	33.6%	32.2%	87.1%	5.1%	30.1%	21.0%	23.8%	5.3%	32.1%	29.6%	25.5%
Net Income Margin	29.6%	38.0%	60.6%	-3.2%	33.3%	35.4%	14.3%	5.1%	33.4%	29.3%	33.8%
Normalized Net Income Margin	31.8%	28.1%	26.1%	13.7%	27.7%	28.4%	22.1%	14.7%	34.3%	28.9%	30.0%
Free Cash Flow Margin	9.4%	16.1%	31.1%	30.6%	26.6%	31.4%	14.9%	41.4%	27.3%	56.7%	42.4%
Asset Turnover											
Total Asset Turnover	0.3x	0.3x	0.3x	0.3x	0.3x	0.3x	0.2x	0.3x	0.3x	0.3x	0.4x
Fixed Asset Turnover	3.8x	3.7x	3.7x	3.6x	3.2x	3.0x	2.8x	2.8x	3.3x	3.9x	4.8x
Accounts Receivable Turnover	5.7x	5.5x	5.5x	6.7x	4.8x	4.6x	4.2x	5.7x	4.7x	5.6x	6.3x
Inventory Turnover	1.4x	1.3x	1.3x	1.3x	1.1x	1.0x	0.9x	1.7x	1.3x	1.8x	2.7x
Short Term Liquidity											
Current Ratio	1.5x	1.5x	0.9x	0.9x	1.0x	1.4x	1.4x	1.4x	1.5x	1.4x	1.4x
Quick Ratio	0.7x	0.7x	0.5x	0.4x	0.6x	0.6x	0.6x	0.8x	0.9x	0.9x	1.0x
Cash from Ops. To Curr Liab	0.4x	0.4x	0.2x	0.3x	0.3x	0.3x	0.3x	0.5x	0.5x	0.6x	0.7x
Ave. Davs Sales Out.	64.4x	66.7x	66.8x	54.5x	76.3x	79.9x	87.0x	64.2x	78.9x	65.9x	58.6x
Ave. Davs Inventory Out.	264.8x	275.4x	279.4x	274.3x	325.3x	361.6x	405.6x	318.2x	286.2x	200.7x	137.8x
Ave. Davs Pavaible Out.	133.0x	136.4x	139.8x	168.8x	154.1x	163.1x	164.7x	155.1x	135.1x	91.8x	69.8x
Ave. Cash Conversion Cvcle	196.2x	205.6x	206.4x	160.1x	247.5x	278.4x	328.0x	227.3x	230.0x	174.8x	126.6x
Long Term Solvency											
Total Debt/Equity	78.5%	80.0%	82.5%	84.2%	80.0%	98.5%	96.4%	65.0%	57.6%	55.8%	52.5%
Total Debt/Capital	44.0%	44.5%	45.2%	45.7%	44.5%	49.6%	49.1%	39.4%	36.6%	35.8%	34.4%
LT Debt/Equity	62.6%	62.5%	57.0%	58.6%	55.8%	78.6%	76.3%	60.5%	51.5%	50.5%	47.9%
LT Debt/Capital	34.8%	34.5%	31.1%	31.6%	30.8%	39.4%	38.7%	36.5%	32.6%	32.3%	31.3%
Total Liabilities/Total Assets	43.0%	41.1%	39.9%	39.9%	40.3%	45.3%	44.3%	42.0%	39.9%	37.6%	34.3%
EBIT / Interest Exp.	12.23x	10.97x	27.00x	1.28x	7.78x	5.65x	7.10x	1.77x	13.93x	17.76x	18.90x
EBITDA / Interest Exp.	16.76x	15.12x	31.05x	4.33x	10.77x	8.91x	11.06x	4.78x	17.57x	21.96x	23.08x
(EBITDA-CAPEX) / Interest Exp.	15.48x	13.89x	29.67x	2.96x	9.62x	7.67x	9.43x	2.52x	15.93x	20.25x	21.16x
Total Debt/EBITDA	2.19x	2.24x	1.88x	2.02x	2.13x	2.90x	4.83x	3.19x	2.71x	2.14x	1.81x
Net Debt/EBITDA	1.64x	1.63x	1.57x	1.66x	1.71x	2.38x	4.02x	2.74x	1.78x	0.96x	0.46x
Altman Z Score	5.17	5.12	4.74	3.84	4.44	3.91	3.6	4.18	4.16	4.04	4.19
Growth Over Prior Year											
Total Revenue	1.6%	(1.5%)	(4.6%)	(25.2%)	(23.1%)	(25.6%)	(19.0%)	11.8%	44.6%	92.4%	134.4%
Gross Profit	3.3%	1.3%	(5.0%)	(23.3%)	(23.8%)	(24.8%)	(17.9%)	4.8%	27.4%	48.4%	70.7%
EBITDA	9.7%	6.2%	136.1%	(54.5%)	(30.6%)	(44.4%)	(70.0%)	(7.6%)	40.6%	112.1%	96.7%
EBITA	8.8%	5.5%	144.3%	(57.2%)	(30.6%)	(46.0%)	(71.8%)	(3.6%)	43.0%	122.4%	103.0%
EBIT	11.8%	7.3%	193.4%	(77.1%)	(31.3%)	(51.4%)	(77.8%)	15.8%	54.3%	170.8%	150.9%
Earnings from Cont. Ops.	8.9%	30.3%	86.8%	172.3%	(36.2%)	(48.5%)	(88.1%)	(133.4%)	96.4%	113.7%	790.6%
Net Income	9.1%	30.3%	86.7%	(14.5%)	(13.6%)	(30.9%)	(80.9%)	(77.6%)	45.4%	59.4%	454.5%
Normalized Net Income	15.7%	4.2%	(12.0%)	(199.8%)	(32.9%)	(24.8%)	(31.4%)	20.8%	78.7%	95.5%	217.4%
Diluted EPS before Extra	15.3%	36.9%	97.1%	171.4%	(35.3%)	(48.3%)	(88.2%)	(131.6%)	95.5%	113.0%	787.5%
Accounts Receivable	1.6%	(0.8%)	(5.8%)	(15.6%)	2.9%	(6.8%)	6.1%	17.1%	(0.2%)	16.0%	18.8%
Inventory	(1.5%)	2.0%	0.5%	(5.9%)	4.9%	4.0%	13.1%	13.8%	0.8%	4.5%	(7.0%)
Net PP&E	5.6%	6.3%	6.9%	6.5%	(4.8%)	(4.6%)	(0.0%)	7.3%	(0.2%)	0.8%	0.2%
Total Assets	(5.6%)	(5.3%)	1.6%	5.1%	7.0%	13.9%	5.0%	(8.0%)	(4.5%)	(4.5%)	0.1%
Tangible Book Value	(10.8%)	(13.4%)	14.9%	(22.2%)	(2.6%)	3.3%	(21.9%)	(22.6%)	(67.5%)	(74.1%)	(99.6%)
Common Equity	(16.2%)	(14.6%)	(8.7%)	(0.4%)	10.6%	8.0%	0.3%	0.2%	5.6%	8.9%	16.0%
Cash from Ops.	(14.4%)	(32.1%)	(14.2%)	(70.5%)	84.5%	36.2%	(53.7%)	49.2%	44.8%	217.8%	418.1%
Capital Expenditures	19.2%	13.0%	3.3%	(17.1%)	(2.4%)	(4.6%)	(0.7%)	38.2%	23.4%	18.2%	11.2%
Levered Free Cash Flow	(22.5%)	(37.7%)	(16.3%)	(21.0%)	116.8%	45.3%	(61.2%)	51.2%	48.4%	247.3%	567.4%
Unlevered Free Cash Flow	85.5%	(90.9%)	(28.6%)	(42.2%)	(171.7%)	659.2%	(130.0%)	125.6%	213.0%	768.9%	(1,475.6%)
Dividend per Share	5.9%	5.9%	5.9%	5.9%	5.6%	5.6%	5.6%	5.6%	2.6%	2.6%	2.6%

CAGR Over Two Years

Total Revenue	1.3%	1.4%	(1.9%)	(12.7%)	(11.6%)	(14.4%)	(12.1%)	(8.6%)	5.4%	19.6%	37.8%
Gross Profit	1.8%	2.2%	(1.2%)	(10.5%)	(11.3%)	(12.7%)	(11.7%)	(10.3%)	(1.5%)	5.6%	18.4%
EBITDA	4.3%	5.2%	55.8%	(31.9%)	(12.8%)	(23.1%)	(15.8%)	(35.2%)	(1.2%)	8.6%	(23.1%)
EBITA	3.8%	4.9%	59.1%	(33.9%)	(13.1%)	(24.6%)	(17.0%)	(35.8%)	(0.4%)	9.6%	(24.4%)
FRIT	4.9%	6.8%	73.6%	(57.0%)	(12.4%)	(27.8%)	(19.4%)	(48.5%)	3.0%	14.7%	(25.4%)
Earnings from Cont. Ops.	11.5%	28.2%	63.9%	--	(16.6%)	(18.1%)	(52.8%)	--	12.0%	4.9%	3.1%
Net Income	11.6%	28.1%	64.4%	--	(2.9%)	(5.1%)	(40.2%)	--	12.1%	5.0%	3.0%
Normalized Net Income	14.1%	3.4%	0.6%	(31.1%)	(11.9%)	(11.5%)	(22.3%)	--	9.5%	21.3%	47.6%
Diluted EPS before Extra	15.5%	32.1%	70.1%	--	(13.6%)	(15.9%)	(51.8%)	--	12.5%	4.9%	2.2%
Accounts Receivable	3.9%	1.7%	(2.9%)	(9.2%)	2.2%	(3.8%)	(0.1%)	(0.6%)	1.4%	4.0%	12.3%
Inventory	4.1%	4.2%	1.9%	(3.4%)	1.7%	3.0%	6.6%	3.5%	2.8%	4.3%	2.5%
Net PP&F	5.5%	5.1%	5.4%	1.4%	0.2%	0.7%	1.3%	6.9%	(2.5%)	(1.9%)	(1.9%)
Total Assets	(4.0%)	(3.7%)	(0.5%)	(1.2%)	0.5%	3.9%	3.3%	(1.6%)	1.1%	4.3%	2.5%
Tangible Book Value	(20.4%)	(22.7%)	(11.7%)	(21.6%)	(6.8%)	(5.4%)	(5.2%)	(22.4%)	(43.8%)	(48.3%)	(94.4%)
Common Equity	0.3%	1.0%	3.5%	(5.9%)	(3.7%)	(4.0%)	(4.3%)	(0.1%)	8.0%	8.5%	7.8%
Cash from Ops.	3.5%	(10.2%)	(4.0%)	(27.1%)	25.7%	(3.9%)	(37.0%)	9.0%	63.5%	108.0%	55.0%
Capital Expenditures	13.4%	3.4%	12.1%	(9.9%)	7.9%	3.8%	1.3%	7.1%	9.7%	6.2%	5.1%
Levered Free Cash Flow	0.4%	(12.6%)	(5.7%)	(29.2%)	29.6%	(4.9%)	(43.0%)	9.3%	79.4%	124.6%	60.8%
Unlevered Free Cash Flow	6.0%	(61.6%)	(12.7%)	(48.1%)	--	(17.0%)	--	14.2%	--	712.2%	103.3%
Dividend per Share	6.1%	6.1%	6.1%	6.1%	5.7%	5.7%	5.7%	5.7%	4.1%	4.1%	4.1%

CAGR Over Three Years

Total Revenue	0.3%	0.3%	(0.9%)	(8.5%)	(7.6%)	(8.5%)	(7.9%)	(5.2%)	4.2%	12.1%	21.9%
Gross Profit	1.7%	2.3%	0.4%	(7.0%)	(7.6%)	(7.7%)	(7.1%)	(5.7%)	0.1%	4.2%	10.0%
FRITDA	4.4%	6.5%	47.2%	(17.2%)	(9.0%)	(14.9%)	(10.0%)	(24.6%)	2.3%	7.8%	11.7%
EBITDA	4.6%	7.1%	45.4%	(17.7%)	(9.3%)	(15.9%)	(10.6%)	(25.1%)	2.6%	8.2%	11.8%
EBIT	4.3%	7.1%	54.1%	(31.1%)	(8.9%)	(17.9%)	(12.6%)	(35.7%)	5.8%	12.2%	17.7%
Earnings from Cont. Ops.	8.5%	34.8%	78.3%	(210.9%)	(7.4%)	(5.4%)	(31.5%)	(69.5%)	10.9%	12.8%	25.7%
Net Income	8.5%	35.1%	78.3%	(175.8%)	2.4%	4.3%	(19.7%)	(63.6%)	11.1%	12.8%	25.6%
Normalized Net Income	4.6%	(0.6%)	5.9%	(17.8%)	(4.4%)	(7.0%)	(11.5%)	(16.9%)	11.5%	15.3%	24.2%
Diluted EPS before Extra	11.5%	39.2%	83.5%	(216.6%)	(4.8%)	(3.4%)	(30.2%)	(69.0%)	13.4%	14.7%	27.2%
Accounts Receivable	2.0%	2.3%	(1.4%)	(6.3%)	3.6%	(1.2%)	0.0%	(1.2%)	1.4%	2.4%	5.9%
Inventory	1.9%	2.6%	3.1%	1.4%	4.3%	4.1%	5.5%	2.0%	1.4%	3.5%	1.8%
Net PP&E	2.8%	2.8%	4.1%	2.3%	2.0%	1.8%	2.2%	3.3%	0.1%	0.7%	0.9%
Total Assets	(1.6%)	(2.9%)	(1.5%)	(0.8%)	(0.5%)	1.8%	1.3%	(3.5%)	(1.2%)	1.0%	2.2%
Tangible Book Value	7.7%	(1.8%)	(8.9%)	(24.0%)	(14.8%)	(14.9%)	(15.2%)	(21.9%)	(34.4%)	(38.6%)	(84.6%)
Common Equity	(2.3%)	(1.7%)	0.9%	2.0%	3.6%	3.3%	2.4%	(3.9%)	(0.7%)	0.1%	2.0%
Cash from Ops.	(2.1%)	(10.2%)	(1.6%)	(13.1%)	25.5%	3.2%	(24.7%)	(7.4%)	31.8%	43.2%	27.2%
Capital Expenditures	15.2%	6.1%	9.4%	(6.2%)	7.8%	0.7%	7.6%	3.9%	12.8%	8.4%	4.5%
Levered Free Cash Flow	(6.4%)	(12.7%)	(2.9%)	(14.2%)	29.8%	3.5%	(29.9%)	(8.8%)	35.6%	46.5%	29.4%
Unlevered Free Cash Flow	32.6%	(54.5%)	(7.9%)	(28.0%)	(193.1%)	3.9%	(161.2%)	(15.2%)	(260.9%)	81.5%	43.4%
Dividend per Share	6.3%	6.3%	6.3%	6.3%	5.9%	5.9%	5.9%	5.9%	4.7%	4.7%	4.7%

CAGR Over Five Years

Total Revenue	2.9%	0.8%	0.5%	(4.4%)	(1.5%)	(3.6%)	(3.2%)	(3.6%)	2.3%	7.6%	13.1%
Gross Profit	2.8%	0.7%	0.2%	(4.3%)	(2.0%)	(3.6%)	(3.5%)	(3.8%)	0.4%	3.6%	7.2%
EBITDA	4.2%	1.8%	20.5%	(12.4%)	(0.5%)	(7.4%)	(3.8%)	(12.6%)	2.1%	7.4%	11.2%
EBITA	4.1%	1.9%	21.4%	(13.2%)	(0.5%)	(8.0%)	(4.3%)	(12.2%)	2.5%	8.1%	11.9%
EBIT	4.9%	1.6%	24.6%	(24.4%)	(0.0%)	(10.4%)	(6.1%)	(19.7%)	3.8%	10.0%	15.2%
Earnings from Cont. Ops.	11.4%	11.6%	23.5%	(196.3%)	0.9%	(0.2%)	(15.5%)	(216.0%)	9.9%	22.0%	43.2%
Net Income	10.8%	11.6%	23.6%	(177.2%)	7.1%	5.8%	(7.2%)	(228.1%)	9.9%	22.1%	43.2%
Normalized Net Income	7.2%	3.9%	1.4%	(13.0%)	2.8%	(0.9%)	(6.5%)	(3.4%)	6.5%	7.6%	20.9%
Diluted EPS before Extra	14.2%	14.6%	26.5%	(199.0%)	3.0%	1.8%	(14.0%)	(214.9%)	11.9%	24.3%	45.2%
Accounts Receivable	0.4%	(1.2%)	(1.1%)	(4.2%)	2.1%	0.4%	1.0%	(0.6%)	1.8%	3.0%	3.9%
Inventory	5.8%	5.7%	5.3%	4.5%	7.8%	8.1%	3.9%	1.4%	2.3%	3.3%	2.9%
Net PP&E	3.6%	4.0%	4.5%	3.9%	4.0%	4.3%	1.0%	2.1%	0.6%	0.9%	1.7%
Total Assets	(2.0%)	(2.0%)	(0.1%)	0.0%	0.7%	2.0%	0.9%	(1.6%)	(0.5%)	(0.1%)	0.1%
Tangible Book Value	63.2%	55.0%	100.7%	29.4%	28.3%	30.5%	3.7%	(7.2%)	(17.0%)	(24.0%)	(70.1%)
Common Equity	(5.4%)	(4.9%)	(3.5%)	(2.4%)	(0.7%)	(0.8%)	(0.5%)	(0.5%)	1.7%	2.2%	3.6%
Cash from Ops.	(10.4%)	(8.6%)	0.2%	(7.6%)	35.7%	(2.8%)	(16.1%)	2.8%	20.2%	25.7%	18.0%
Capital Expenditures	9.5%	11.5%	15.5%	9.9%	13.4%	12.1%	14.2%	5.1%	13.0%	6.1%	7.6%
Levered Free Cash Flow	(14.1%)	(11.0%)	(1.2%)	(9.4%)	43.5%	(4.2%)	(20.2%)	2.5%	21.4%	27.4%	18.8%
Unlevered Free Cash Flow	(196.2%)	(42.9%)	(5.2%)	(19.6%)	(184.8%)	(14.1%)	(172.0%)	1.3%	(239.3%)	44.0%	26.4%
Dividend per Share	6.7%	6.7%	6.7%	6.7%	6.3%	6.3%	6.3%	6.3%	5.4%	5.4%	5.4%

Ticker: **PFE US EQUITY** PFE US EQUITY Ascend Currency Reporting Change USD
 Period Type: **Annuals** Consolidated Yes Accounting Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

REVENUE											
Revenue by Product											
For the Fiscal Period Ending	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Revenue	67,057.00	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	41,172.00	41,908.00
Biopharma	58,523.00	61,971.00	51,214.00	47,878.00	25,600.00	26,758.00	29,197.00	31,422.00	37,558.00	38,344.00	41,908.00
Other	8,534.00	3,288.00	3,443.00	3,706.00	24,005.00	22,093.00	23,627.00	21,124.00	12,484.00	2,828.00	-
Rare Disease	-	-	-	-	-	-	-	-	3,605.00	-	-
Oncology	-	-	-	-	-	-	-	-	-	-	-
Internal Medicine	-	-	-	-	-	-	-	-	-	-	-
Hospital	-	-	-	-	-	-	-	-	-	-	-
Vaccines	-	-	-	-	-	-	-	-	-	-	-
Inflammation & Immunology (I&I)	-	-	-	-	-	-	-	-	-	-	-
Reconciling Items	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography											
For the Fiscal Period Ending	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
Revenue	67,057.00	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	41,172.00	41,908.00
United States	28,855.00	26,933.00	21,313.00	20,274.00	19,073.00	21,704.00	26,369.00	26,026.00	25,329.00	20,593.00	21,712.00
Emerging Markets	16,345.00	16,099.00	12,545.00	11,739.00	11,719.00	11,386.00	10,420.00	11,400.00	12,651.00	8,828.00	8,372.00
Developed Europe	11,849.00	11,252.00	10,843.00	11,225.00	11,499.00	9,713.00	9,304.00	8,510.00	9,116.00	7,729.00	7,788.00
Developed Rest of World	10,008.00	10,975.00	9,956.00	8,346.00	7,314.00	6,298.00	6,731.00	6,610.00	6,551.00	4,022.00	4,037.00
International	-	-	-	-	-	-	-	-	-	-	-
Rare Disease	-	-	-	-	-	-	-	-	-	-	-
Oncology	-	-	-	-	-	-	-	-	-	-	-
Oncology	-	-	-	-	-	-	-	-	-	-	-
Vaccines	-	-	-	-	-	-	-	-	-	-	-
Vaccines	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker: PFE US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated Yes	Accounting Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Pension	31/12/2010	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020
For the Fiscal Period Ending	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	606.00	630.00	607.00	543.00	472.00	495.00	440.00	464.00	136.00	125.00	146.00
Interest Cost	1,244.00	1,249.00	1,165.00	1,111.00	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00
Expected Return on Plan Assets	(1,217.00)	(1,308.00)	(1,407.00)	(1,406.00)	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,321.00)
Pension Expense (Income)	1,081.00	994.00	926.00	928.00	402.00	1,203.00	696.00	695.00	(2.00)	331.00	70.00
Other Postretirement Cost											
Service Cost	79.00	68.00	68.00	61.00	55.00	55.00	41.00	42.00	39.00	37.00	38.00
Interest Cost	211.00	195.00	182.00	166.00	169.00	117.00	101.00	90.00	72.00	75.00	49.00
Expected Return on Plan Assets	(31.00)	(35.00)	(46.00)	(55.00)	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(36.00)
Other Postretirement Benefits Expense (I	232.00	127.00	129.00	163.00	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(118.00)
Pension Funded Status											
Fair Value of Plan Assets	17,295.00	18,958.00	20,129.00	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00
Actual Return (Loss) on Plan Assets	1,577.00	574.00	2,132.00	2,294.00	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	2,842.00
Employer Contribution	1,754.00	2,640.00	585.00	557.00	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	1,629.00
Benefits Paid	(1,037.00)	(989.00)	(912.00)	(1,017.00)	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)
Projected Benefit Obligation	23,568.00	25,157.00	28,044.00	25,633.00	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00
Over(Under) Funded Pension	(6,273.00)	(6,199.00)	(7,915.00)	(4,514.00)	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)
Accumulated Benefit Obligation	17,199.00	19,470.00	22,391.00	18,346.00	--	--	--	--	--	--	--
Pension Funding Ratio	73.38	75.36	71.78	82.39	73.80	76.89	75.84	80.36	80.64	81.33	85.48
Other Postretirement Funded Status											
Fair Value of Plan Assets	414.00	422.00	644.00	741.00	762.00	622.00	458.00	494.00	469.00	519.00	588.00
Actual Return (Loss) on Plan Assets	46.00	9.00	85.00	98.00	45.00	(3.00)	44.00	39.00	(22.00)	50.00	69.00
Employer Contribution	249.00	250.00	353.00	244.00	210.00	84.00	16.00	183.00	145.00	137.00	113.00
Benefits Paid	(273.00)	(296.00)	(274.00)	(314.00)	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	(201.00)
Projected Benefit Obligation	3,582.00	3,900.00	4,165.00	3,438.00	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00
Over(Under) Funded Post Ret Benefits	(3,168.00)	(3,478.00)	(3,521.00)	(2,697.00)	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)
Other Post-Retirement Funding Ratio	11.56	10.82	15.46	21.55	24.05	25.25	20.32	24.36	25.08	31.13	47.50
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	7.89	7.58	7.52	7.37	7.41	8.30	7.07	8.00	7.50	7.20	7.00
Discount Rate used on Plan Liabilities	5.47	4.95	4.10	4.66	3.74	4.50	3.78	3.80	4.40	3.30	2.60
Rate of Compensation Increase	3.81	3.43	2.85	2.92	2.76	2.80	2.74	2.80	2.80	-	-
Other Postretirement Benefits											
Expected Return on Plan Assets	8.50	8.50	8.50	8.50	8.50	8.30	8.00	8.00	7.50	7.30	7.00
Discount Rate used on Plan Liabilities	5.60	4.80	4.10	5.10	4.20	4.50	4.20	3.70	4.30	3.20	2.50
Health Care Cost Trend Projected(next y	8.00	7.80	7.50	7.30	7.00	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	17,295.00	18,958.00	20,129.00	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00
Asset Category - Equities %	39.82	41.12	48.03	51.65	41.23	40.20	40.10	37.50	31.30	31.80	28.40
Asset Category - Debt %	32.83	31.26	33.79	30.05	34.52	35.00	34.90	39.60	47.10	48.70	50.20
Asset Category - Real Estate %	12.13	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	9.91	12.71	3.31	2.79	5.84	3.60	5.30	4.60	3.40	2.50	4.90
Asset Category - Other %	--	9.77	10.02	11.36	18.41	21.20	19.70	18.30	18.20	17.00	16.60
Expected Pension Payments											
Year 1	1,466.00	1,398.00	1,721.00	1,368.00	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00
Year 2	1,159.00	1,382.00	1,319.00	1,313.00	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00
Year 3	1,204.00	1,415.00	1,329.00	1,320.00	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00
Year 4	1,391.00	1,420.00	1,353.00	1,396.00	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00
Year 5	1,334.00	1,435.00	1,412.00	1,511.00	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00
Beyond Year 5	7,864.00	8,093.00	7,552.00	7,383.00	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00
Expected Postretirement Benefits											
Year 1	293.00	295.00	295.00	286.00	261.00	198.00	186.00	173.00	166.00	153.00	97.00
Year 2	302.00	308.00	306.00	285.00	211.00	205.00	196.00	179.00	171.00	137.00	94.00
Year 3	310.00	317.00	313.00	293.00	216.00	208.00	198.00	181.00	171.00	137.00	92.00
Year 4	321.00	326.00	321.00	303.00	220.00	208.00	197.00	179.00	168.00	136.00	89.00
Year 5	328.00	331.00	329.00	311.00	222.00	207.00	196.00	173.00	165.00	134.00	86.00
Beyond Year 5	1,742.00	1,780.00	1,748.00	1,661.00	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00

